Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 2 days ago

Tango Therapeutics, Inc.: FARALLON CAPITAL MANAGEMENT, L.L.C. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Farallon Capital Management amended its Schedule 13G filing on Tango Therapeutics, updating its disclosed stake in the biotech company. The filing, submitted under SEC accession number 0000908834-26-000536, reflects the investment firm's revised position. The amendment signals a change in Farallon's holdings, though the filing did not specify the size or direction of the adjustment. Investors watch 13G amendments for clues about institutional conviction in small-cap biotech names like Tango. Further detail on the exact share count and percentage owned would clarify whether Farallon increased or trimmed its exposure.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Farallon Capital Management, L.L.C., Tango Therapeutics, Inc.